XPA-210: A new proliferation marker to characterize tumor biology and progression of renal cell carcinoma

World Journal of Urology

Volumn 29, Issue 6, 2011, Pages 801-806

  Gakis, Georgios ^a   Hennenlotter, Joerg ^a   Scharpf, Marcus ^a   Hevler, Joachim ^b   Schilling, David ^a   Kuehs, Ursula ^a   Stenzl, Arnulf ^a   Schwentner, Christian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Matritech Medical Products   (Germany)

Author keywords

Clear cell renal cell carcinoma; Localized disease; Metastatic disease; Proliferation marker; XPA 210

Indexed keywords

EXPOSED PROLIFERATION ANTIGEN 210; PEPTIDE FRAGMENT; THYMIDINE KINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; DISEASE COURSE; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PILOT STUDY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PILOT PROJECTS; RETROSPECTIVE STUDIES; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL;

EID: 81855166691     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0621-8     Document Type: Article

References (23)

1. He Q, Skog S, Welander I, Tribukait B (2002) X-irradiation effects on thymidine kinase (TK): I. TK1 and 2 in normal and malignant cells. Cell Prolif 35: 69-81.
2. Elsevier SM, Kucherlapati RS, Nichols EA, Creagan RP, Giles RE, Ruddle FH, Willecke K, McDougall JK (1974) Assignment of the gene for galactokinase to human chromosome 17 and its regional localisation to band q21-22. Nature 251: 633-636.
3. Willecke K, Teber T, Kucherlapati RS, Ruddle FH (1977) Human mitochondrial thymidine kinase is coded for by a gene on chromosome 16 of the nucleus. Somatic Cell Genet 3: 237-245.
4. Broët P, Romain S, Daver A, Ricolleau G, Quillien V, Rallet A, Asselain B, Martin PM, Spyratos F (2001) Thymidine kinase as a proliferative marker: clinical relevance in 1, 692 primary breast cancer patients. J Clin Oncol 19: 2778-2787.
5. Chen Y, Ying M, Chen Y, Hu M, Lin Y, Chen D, Li X, Zhang M, Yun X, Zhou J, He E, Skog S (2010) Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1, 247 cancer patients in routine clinical settings. Int J Clin Oncol [Epub ahead of print].
6. Eriksson S, Munch-Petersen B, Johansson K, Eklund H (2002) Structure and function of cellular deoxyribonucleoside kinases. Cell Mol Life Sci 59: 1327-1346.
7. He Q, Mao Y, Wu J, Decker C, Merza M, Wang N, Eriksson S, Castro J, Skog S (2004) Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int J Oncol 25: 945-953.
8. Zhang J, Jia Q, Zou S, Zhang P, Zhang X, Skog S, Luo P, Zhang W, He Q (2006) Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 15: 455-461.
9. Mao Y, Wu J, Skog S, Eriksson S, Zhao Y, Zhou J, He Q (2005) Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling. Oncol Rep 13: 837-846.
10. Sugasawa H, Ichikura T, Ono S, Tsujimoto H, Hiraki S, Sakamoto N, Yaguchi Y, Shimazaki H, Yamamoto J, Hase K (2010) Isolated gastric metastasis from renal cell carcinoma 19 years after radical nephrectomy. Int J Clin Oncol 15: 196-200.
11. Makar R, Mason A, Kittelson JM, Bowden GT, Cress AE, Nagle RB (1994) Immunohistochemical analysis of cathepsin D in prostate carcinoma. Mod Pathol 7: 747-751.
12. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr (1997) p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 158: 131-137.
13. Gronowitz JS, Kallander FR, Diferholm H, Hagberg H, Petterssion U (1984) Application of an in vivo assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 15: 5-12.
14. Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-Hallek I, Thiel E, Emmerich B (1999) Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 93: 1732-1737.
15. Wu CJ, Yang RJ, Zhou J, Bai S, Zou L, Mao YR, He Q (2003) Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods 277: 157-169.
16. Zou L, Zhang PG, Zou S, Li Y, He Q (2002) The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Markers 17: 135-140.
17. Kuroiwa N, Nakayama M, Fukuda T, Fukui H, Ohwada H, Hiwasa T, Fujimura S (2001) Specific recognition of cytosolic thymidine kinase in the human lung tumor by monoclonal antibodies raised against recombinant human thymidine kinase. J Immunol Methods 253: 1-11.
18. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, Sinescu IC (2007) Renal cell carcinoma guideline. Eur Urol 51: 1502-1510.
19. Tunio MA, Hashmi A, Rafi M (2010) Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials. Ann Oncol [Epub ahead of print].
20. Chen Z, Zhou H, Li S, He E, Hu J, Zhou J, Skog S (2008) Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours. Anticancer Res 28: 3897-3907.
21. Pan ZL, Ji XY, Shi YM, Zhou J, He E, Skog S (2010) Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients. J Cancer Res Clin Oncol [Epub ahead of print].
22. Fujiwara H, Arima N, Ohtsubo H, Matsumoto T, Kukita T, Kawada H, Imaizumi R, Ozaki A, Matsushita K, Tei C (2002) Clinical significance of serum neuron-specific enolase in patients with adult T-cell leukemia. Am J Hematol 71: 80-84.
23. Luo P, He E, Eriksson S, Zhou J, Hu G, Zhang J, Skog S (2009) Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker. Eur J Cancer Prev 18: 220-224.